Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group

Tadashi Kumamoto¹ · Hiroaki Goto² · Chitose Ogawa¹ · Toshinori Hori³ · Takao Deguchi⁴ · Takuya Araki⁵ · Akiko M. Saito⁶ · Atsushi Manabe⁷ · Keizo Horibe⁶ · Hidemi Toyoda⁸

Published online: 23 January 2021
© Japanese Society of Hematology 2021

Correction to:
International Journal of Hematology (2020) 112:720–724
<https://doi.org/10.1007/s12185-020-02962-2>

In the original publication of the article, Table 1 was incorrectly published. The correct Table 1 is given in this correction.

The original article can be found online at <https://doi.org/10.1007/s12185-020-02962-2>.

✉ Tadashi Kumamoto
tkumamot@ncc.go.jp

- ¹ Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
- ² Department of Hematology and Oncology, Children's Cancer Center, Kanagawa Children's Medical Center, Yokohama, Japan
- ³ Department of Pediatrics, Aichi Medical University Hospital, Nagoya, Japan
- ⁴ Division of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan
- ⁵ Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
- ⁶ Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
- ⁷ Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
- ⁸ Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Mie, Japan

Table 1 The study design of FLEND (ALL-RT11)

	Number of patients	Etoposide (mg/m ² /day)	Fludarabine (mg/m ² /day)	Nelarabine (mg/m ² /day)
Administration ^a		1 h div	0.5 h div after ETP	1 h div 4 h after FLD
Phase 1 ^b				
Dose level				
– 2	3–6	50	20	650
– 1	3–6	75	20	650
1	3–6	75	30	650
2	3–6	100	30	650
Phase 2 ^c	22–25	RP2D	RP2D	650

FLD fludarabine, *NEL* nelarabine, *RP2D* recommended phase 2 dose

^aAll agents were administered for 5 consecutive days

^b3 + 3 design, the dose-finding study was started from dose-level 1

^cSimon's 2-stage optimal design, div intravenous drip

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.